Novartis’ Scemblix approved by the EC for adults with chronic myeloid leukaemia
It is estimated that every year more than 6,300 people will be diagnosed with CML in Europe
Read More
Tag: Scemblix
Novartis receives vital licence for Scemblix
Therapy represents the first STAMP inhibitor for patients with chronic myeloid leukaemia
Read More
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
- Fabentech secures French approval for Ricimed antidote
